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Abstract
Background: Several studies have assessed natriuretic peptides in patients with thyroid disorders, and these studies have provided contrast-
ing results. This difference may be partially explained by the presence of concomitant disorders of the cardiovascular system in participants.
Material and methods: The study included 101 patients free of any cardiovascular disorder, who, on the basis of plasma levels of TSH 
and thyroid hormones, were divided into patients with overt hyperthyroidism, patients with subclinical hyperthyroidism, patients with 
overt hypothyroidism, patients with subclinical hypothyroidism, and control subjects with normal thyroid profile. Hyperthyroidism was 
induced either by nodular thyroid disease or by Graves’ disease, while hypothyroidism was secondary to autoimmune thyroiditis or surgery.
Results: Compared to control subjects, hyperthyroid patients were characterised by higher plasma levels of NT-pro-BNP. This increase 
was particularly pronounced in cases of overt disease. On the other hand, neither clinical nor subclinical hypothyroidism was associated 
with any significant changes in this peptide. Plasma levels of NT-pro-BNP did not differ between patients with Graves’ disease and toxic 
nodular goitre nor between patients with autoimmune hypothyroidism and hypothyroidism secondary to thyroidectomy. Only L-thyroxine 
substitutions, but not hyperthyroidism treatment, caused changes in plasma concentration of NT-pro-BNP.
Conclusions: Hyperthyroidism and hypothyroidism induce changes of the plasma concentration of NT-pro-BNP. Although both exogenous 
L-thyroxine and antithyroid drugs restored thyroid function, only the former drug changed plasma NT-pro-BNP content. The thyro-
metabolic state of a patient should always be taken into consideration when NT-pro-BNP is assessed as a marker of cardiac dysfunction.
(Pol J Endocrinol 2011; 62 (6): 523–528)
Key words: hyperthyroidism, hypothyroidism, L-thyroxine, brain natriuretic peptide, BNP, NT-pro-BNP
Streszczenie
Wstęp: W dotychczas przeprowadzonych badaniach oceniano stężenia peptydów natriuretycznych u osób z chorobami tarczycy, 
dostarczyły one jednak rozbieżnych wyników. Różnice te można częściowo tłumaczyć obecnością współistniejących schorzeń układu 
sercowo-naczyniowego.
Materiał i metody: Badaniem objęto 101 pacjentów, u których nie stwierdzono schorzeń układu sercowo-naczyniowego. Na podstawie 
wyników oznaczeń stężeń w osoczu TSH i wolnych hormonów tarczycy uczestników badania podzielono na chorych z klinicznie jawną 
nadczynnością tarczycy, chorych z subkliniczną nadczynnością tarczycy, pacjentów z klinicznie jawną niedoczynnością tarczycy, pacjentów 
z subkliniczną niedoczynnością tarczycy i osoby bez zaburzeń funkcji gruczołu tarczowego. U podłoża nadczynności tarczycy leżała choroba 
Gravesa-Basedowa lub wole guzowate, podczas gdy niedoczynność miała charakter autoimmunologiczny lub była konsekwencją tyreoidektomii.
Wyniki: W porównaniu z grupą kontrolną u osób z nadczynnością tarczycy stwierdzono wyższe stężenia w osoczu NT-pro-BNP. 
Wzrost ten był szczególnie wyrażony w przypadku klinicznie jawnej nadczynności tarczycy. W klinicznie jawnej oraz w subklinicznej 
niedoczynności tarczycy nie obserwowano zmienionych stężeń tego peptydu. Stężenie NT-pro-BNP w osoczu nie różniło się pomiędzy 
osobami z chorobą Gravesa-Basedowa i chorymi z wolem guzkowym nadczynnym, jak również pomiędzy osobami z niedoczynnością 
tarczycy o podłożu autoimmunologicznym i pozabiegowym. Obserwowano, iż jedynie leczenie niedoczynności tarczycy wiązało się ze 
zmianami stężeń badanego białka we krwi.
Wnioski: Nadczynność i niedoczynność tarczycy w różny sposób wpływają na stężenie NT-pro-BNP w osoczu krwi. Mimo iż zarówno 
egzogenna L-tyroksyna, jak i leczenie tyreostatykiem przywracają prawidłową funkcję tarczycy, jedynie L-tyroksyna wpływa na stężenie 
NT-pro-BNP. Stan tyreometaboliczny chorego powinien być zawsze uwzględniany przy ocenie stężenia NT-pro-BNP jako markera dys-
funkcji serca. (Endokrynol Pol 2011; 62 (6): 523–528)
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Introduction
The natriuretic peptides constitute a group of peptide 
hormones which play important roles in the regulation 
of renal and cardiovascular homeostasis [1]. Brain natriu-
retic peptide (BNP), or B-type natriuretic peptide, is a 32 
amino acid polypeptide secreted by the ventricles and, 
to a lesser extent, by the atria of the heart in response to 
volume expansion, pressure overload, and other kinds of 
myocardial stress associated with increased endocardial 
pressure and excessive stretching of cardiomyocytes [2, 
3]. This cardioprotective peptide is believed to be in-
volved in the regulation of blood pressure, blood volume, 
and sodium balance [4, 5]. After binding to its receptors, 
BNP reduces systemic vascular resistance and central 
venous pressure, leading to an increase in diuresis and 
natriuresis, and to vascular relaxation [2]. During its 
synthesis, a 108 amino acid precursor moiety (pro-BNP) 
is split at a ratio of 1:1 into the physiologically active 
BNP, corresponding to the C-terminal fragment, and the 
biologically inactive N-terminal fragment (NT-pro-BNP), 
consisting of 76 amino acids [5, 6]. The half-life of 
NT-pro-BNP is several times longer than that of BNP 
(1–2 hours vs. 15–20 min) [2, 3]. Measurement of plasma 
levels of BNP or NT-pro-BNP has been recommended in 
the diagnosis and prognosis of patients with symptoms 
of left ventricular dysfunction and for stratification of 
risk in patients with acute coronary syndromes [4, 7, 8]. 
Apart from heart failure and acute coronary syndromes, 
the release of BNP is enhanced in patients with other dis-
orders, including atrial fibrillation, arterial hypertension, 
pulmonary hypertension, dyspnoea or hypertrophic 
cardiomyopathy [1, 9, 10]. Because of its greater stability 
and longer half-life, it is assumed that NT-pro-BNP is also 
a useful marker of cardiac dysfunction, playing a role in 
the diagnosis, management, and prognosis of patients 
with congestive heart failure.
Although some previous studies assessed BNP 
and/or NT-pro-BNP levels in patients with thyroid dys-
function [11–17], the value of the obtained results was 
limited by the fact that these studies either included pa-
tients with heart failure, atrial fibrillation, hypertension 
or other cardiovascular disorders, or excluded patients 
only on the basis of clinical history. This study, which 
assessed echocardiographically diameters of cardiac 
cavities, left ventricle mass and the left ventricle ejection 
fraction, determined NT-pro-BNP in patients free from 
any cardiovascular disorders.
Material and methods
Subjects
The study included 101 patients, without any changes 
in the cardiovascular system, who on the basis of 
plasma levels of TSH, free thyroxine (fT4) and free trii-
odothyronine (fT3) were allotted into one of five groups: 
(A) patients with overt hyperthyroidism (n = 47); (B) 
patients with subclinical hyperthyroidism (n = 16); 
(C) patients with overt hypothyroidism (n = 24); (D) 
patients with subclinical hypothyroidism (n =14); and 
control subjects with normal thyroid profile (n = 30). 
Overt hyperthyroid patients suffered from either nodu-
lar thyroid disease (n = 21) or from Graves’ disease 
(n = 26). In turn, overt hypothyroidism was induced 
by either autoimmune thyroiditis (n = 19) or surgery 
(n = 5).  We excluded all patients with any autoimmune 
disorder (with the exception of thyroid autoimmune 
disorders) or suffering from heart failure, coronary ar-
tery disease, atrial fibrillation, cardiomyopathy or any 
other cardiovascular disorder. The remaining exclusion 
criteria were: decompensated diabetes, hepatic cirrho-
sis, severe renal insufficiency, any organ transplantation 
in the past, any present or previous psychotic disorders, 
depression. alcoholism or drug addiction.
Study protocol
The study protocol was approved by the local bioethical 
committee and written informed consent was obtained 
from each patient. Patients with thyroid dysfunction 
were observed in both baseline conditions (before treat-
ment) and after euthyroidism had been restored. The 
mean daily dose and the mean period of treatment to 
restore euthyroidism were, respectively, 100 mg and 
39 days for L-thyroxine, and 30 mg and 14 days for methi-
mazole. Echocardiography, performed using a standard 
ultrasound system (Vingmed System Five Advantage, 
General Electric, USA), measured left ventricular end-di-
astolic diameter, interventricular septum and posterior 
wall diastolic diameter. Next, left ventricular mass was 
calculated by the Devereaux formula and then indexed 
to the body surface area. Left ventricular ejection fraction 
was measured based on the biplane Simpson method.
Laboratory assays
Blood samples were collected from the antecubital vein 
at 8 am after overnight fasting (12 hours) and collected 
into tubes containing serum. Patients were required to 
refrain from smoking or taking vigorous exercise prior 
to blood sampling. The samples were centrifuged within 
15 min of venipuncture. The plasma samples were then 
separated and stored at –70°C until analysis. Plasma 
levels of TSH and free thyroid hormones were assayed 
immunoenzymatically (MEIA), by routine lab oratory 
techniques (Abbot AxSYM, Abbot Laboratories, USA). 
Thyroperoxidise antibodies (TPOAb) and thyrotropin 
receptor antibodies (TRAb) were measured, respectively, 
by an enzyme-linked immunosorbent assay (ELISA) 
method and by a radioimmune assay (RIA) method. 
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Reference ranges were as follows: TSH — 0.4–4.0 mU/L, 
fT4 — 0.93–1.7 ng/dL, fT3 — 2.0–4.4 pg/mL, thyroid peroxi-
dise antibodies: 12 IU/L, thyroid receptor antibodies: < 2 
IU/mL. Plasma levels of NT-pro-BNP were determined by 
an immunoenzymatic method using polyclonal antibod-
ies, which recognise epitopes located in the N-terminal 
part (ECLIA, Roche Elecsys 2010, USA) (1–76).
Statistical analysis
Results are shown as the mean ± standard deviation 
(SD). Statistical analysis was performed using Statistica 
7.1 package (StatSoft, Inc. Tulsa, OK, USA). Pretreatment 
and post-treatment data within the same group were 
compared with Student’s paired t-test. A p of less than 
0.05 was regarded as statistically significant.
Results
Marked differences in plasma levels of TSH and free thy-
roid hormones were observed between patients belong-
ing to various studied groups (Table I). Individuals with 
clinically overt hyperthyroidism were statistically younger 
than healthy subjects (52.8 ± 13. years vs. 59.9 ± 12.8 
years, p < 0.001) and had a lower body mass index (BMI) 
(23.8 ± 3.9 kg/m2 vs. 28.3 ± 3.7 kg/m2, p < 0.001). No dif-
ferences in age or BMI were observed between control 
subjects and patients with other thyroid disorders.  There 
were no differences in left ventricular mass index. All sub-
jects had this parameter in the normal range.
Compared to control subjects, patients with both 
overt and subclinical hyperthyroidism had higher 
plasma levels of NT-pro-BNP (overt hyperthyroidism: 
1,129.7 ± 1,119.8 pg/ml vs. 138.9 ± 173.3 pg/ml, p < 0.001; 
subclinical hyperthyroidism: 598.1 ± 639.2 pg/ml 
vs. 138.9 ± 173.3 pg/ml, p < 0.001) (Figure 1). Plasma le-
vels of NT-pro-BNP were significantly higher in subjects 
with overt hyperthyroidism than in patients with sub-
clinical hyperthyroidism (p < 0.05). No differences in 
NT-pro-BNP were observed between subjects with toxic 
nodular goitre (1,244.0 ± 2,096.9 pg/ml) and Graves’ dis-
ease (1,037.3 ± 1,598.8 pg/ml) (data not shown). Plasma 
levels of NT-pro-BNP did not differ between patients 
with overt hypothyroidism (190.0 ± 161.2 pg/ml), 
subclinical hypothyroidism (234.1 ± 180.1 pg/ml) and 
control subjects (138.9 ± 173.3 pg/ml) (Figure 1). Plasma 
levels of NT-pro-BNP in subjects with autoimmune 
hypothyroidism (569.1 ± 1,651.8 pg/ml) were similar to 
those observed in patients with post-surgery hypothy-
roidism (239.9 ± 136.7 pg/ml) (data not shown).
Hyperthyroidism treatment did not affect plasma le-
vels of NT-pro-BNP (pretreatment: 1,129.7 ± 1,819.8 pg/ml, 
post-treatment: 1,059.3 ± 1,598.1 pg/ml) (Figure 2). 
No effect of treatment was observed either in pa-
tients with Graves’ disease (1,037.3 ± 1,598.8 pg/ml 
vs. 741.2 ± 773.8 pg/ml)  or subjects with toxic nodular goitre 
(1,244.0 ± 2,096.9 pg/ml vs. 1,453.1 ± 2,198.0 pg/ml). L-thy-
roxine treatment increased plasma levels of NT-pro-BNP 
from 190.0 ± 161.2 pg/ml to 313.3 ± 238.5 pg/ml 
(p < 0.05) when all hypothyroid patients were as-
sessed together (Figure 3). When both subgroups of 
overt hypothyroid patients were assessed separately, 
L-thyroxine produced no significant effect in patients 
with autoimmune hypothyroidism (569.1 ± 1,651.8 pg/ml 
vs. 591.3 ± 1313.7 pg/ml) or in post-surgery hypothy-
roidism: 239.9 ± 136.7 pg/ml vs. 355.3 ± 251.6 pg/ml).
Discussion
Our study has shown that among clinical conditions as-
sociated with thyroid dysfunction, only hyperthyroidism 
was accompanied by higher plasma levels of NT-pro-BNP. 
Increased NT-pro-BNP levels were observed in patients 
with subclinical hyperthyroidism, most of whom were 
asymptomatic and did not have any abnormalities 
on echocardiography. These hyperthyroidism-related 
changes in NT-pro-BNP probably reflect a hypermeta-
bolic condition associated with hyperthyroidism rather 
than being characteristic of any particular clinical entity. 
This hypothesis, which is in line with the observations 
by Schultz et al. [18], is supported by the fact that plasma 
NT-pro-BNP levels were clearly higher in patients with 
overt hyperthyroidism than in subjects with subclinical 
hyperthyroidism, while no differences in plasma levels of 
this peptide were observed between patients with toxic 
nodular goitre and subjects with Graves’ disease, caus-
ing the same degree of thyroid dysfunction. The latter 
finding is in agreement with the observations by other 
authors [11, 12] who noticed similar plasma levels of BNP, 
irrespective of the disorder leading to hyperthyroidism 
(Graves’ disease, nodular and multinodular goitre, 
painless thyroiditis, or subacute thyroiditis). Although 
increased plasma levels of BNP and/or NT-pro-BNP 
have been observed by other authors [11–17], most these 
studies included subjects with heart failure and other car-
diovascular disorders known to elevate plasma BNP and 
NT-pro-BNP, and were limited to overt hyperthyroidism. 
The strength of our report is its very strict inclusion 
and exclusion criteria, which made it possible to link 
the obtained results to hyperthyroidism, and to exclude 
their association with cardiovascular disorders, particu-
larly heart failure and atrial fibrillation. Although our 
overt hyperthyroidism patients differed from healthy 
subjects in age and BMI, they do not seem to be the fac-
tors responsible for higher NT-pro-BNP levels. We think 
this because the levels of these markers were elevated 
even in subjects with subclinical hyperthyroidism, who 
were of a similar age, and had similar BMI and left ven-
tricular mass index, as compared with control patients.
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Figure 3. Effect of L-thyroxine on plasma levels of NT-pro-BNP in hypothyroid patients. Data represents the mean ± SD. 
*P < 0.05 vs. baseline value
Rycina 3. Wpływ L-tyroksyny na stężenie NT-pro-BNP w osoczu chorych na niedoczynność tarczycy. Wyniki przedstawiają średnią 
± odchylenie standardowe. *P < 0.05 vs. wartość przed leczeniem
Figure 1. Plasma levels of NT-pro-BNP in patients with subclinical and clinically overt hyperthyroidism and hypothyroidism. 
Data represents the mean ± SD. ***P < 0.001 vs. control subjects. #P < 0.05 vs. patients with subclinical hyperthyroidism. 
^^^P < 0.001 vs. patients with subclinical hypothyroidism. &&&P < 0.001 vs. patients with overt hypothyroidism
Rycina 1. Stężenie NT-pro-BNP w osoczu chorych na subkliniczne i klinicznie jawne choroby tarczycy. Wyniki przedstawiają 
średnią ± odchylenie standardowe. ***P < 0.001 vs. grupa kontrolna.  #P < 0.05 vs. chorzy na subkliniczną nadczynność tarczycy. 
^^^P < 0.001 vs. chorzy na subkliniczną niedoczynność tarczycy. &&&P < 0.001 vs. chorzy na klinicznie jawną niedoczynność tarczycy
Figure 2. Effect of methimazole on plasma levels of NT-pro-BNP in hyperthyroid patients. Data represents the mean ± SD
Rycina 2. Wpływ metimazolu na stężenie NT-pro-BNP w osoczu chorych na nadczynność tarczycy. Wyniki przedstawiają 
średnią ± odchylenie standardowe
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Unlike hyperthyroidism, the presence of hypothyroid-
ism was not associated with any changes in NT-pro-BNP. 
Although this finding seems at first unexpected, it is, in 
fact, in line with the results of some [11, 12], but not all 
[17], studies. There are two possible explanations for our 
findings. Firstly, the neutral effect of hypothyroidism 
on NT-pro-BNP is a sum of opposite effects of a hypo-
thyroidism-induced hypometabolic state and increased 
production of proinflammatory cytokines and endothe-
lins. Both proinflammatory cytokines and endothelins are 
known stimulators of BNP release [2, 3] and there is some 
evidence on a proinflammatory state and endothelial 
dysfunction in the case of hypothyroidism and thyroid 
autoimmunity [19–21]. Their excess may counterbalance 
the lack of a stimulatory effect of thyroid hormones on 
BNP production. A second, although in our opinion less 
likely, explanation is that BNP release in patients with 
thyroid disorders only reflects interleukin-6 release. Inter-
estingly, in line with this hypothesis, other authors have 
observed that only patients with clinical or subclinical 
hyperthyroidism had increased plasma levels of inter-
leukin-6 [22], while circulating levels of this interleukin 
in subjects with clinical or subclinical hypothyroidism 
did not differ from those observed in healthy subjects.
Another interesting finding of our study is that L-thy-
roxine treatment produced an increase in NT-pro-BNP 
levels. This finding, being in line with the results of 
Schultz et al. [17], probably results from a direct effect of 
exogenous thyroid hormones on the heart. In line with 
our hypothesis, triiodothyronine was found to enhance 
BNP gene transcription in animals [23], while thyroxine 
and triiodothyronine dose-dependently stimulated BNP 
release from cultures of atrial and ventricular cardiomyo-
cytes [13]. Moreover, induction of an acute hyperthyroid 
state in healthy subjects by triiodothyronine administra-
tion increased plasma levels of NT-pro-BNP [24].
In turn, an unexpected observation, being in contrast 
with the findings of other authors [17, 25] was that, despite 
normalisation of plasma levels of TSH and free thyroid 
hormones, antithyroid drugs did not restore a hyper-
thyroidism-induced increase in plasma NT-pro-BNP 
levels. The study protocol does not allow us to explain this 
finding. It cannot be excluded that the time required to nor-
malise BNP production is much longer than that needed to 
restore normal thyroid function. Alternatively, antithyroid 
drugs may produce non-thyroid hormone-related effects, 
which oppose the effect of a decrease in thyroid hormone 
reduction on BNP production.
Conclusions
Our study has shown that hyperthyroidism, in both 
its clinical and subclinical forms, results in a signifi-
cant increase in serum levels of NT-pro-BNP, while no 
changes in the production of BNP were induced by 
hypothyroidism. Although both exogenous L-thyroxine 
and antithyroid drugs restored thyroid function, only 
the former drug changed plasma NT-pro-BNP content. 
Our results indicate that the thyrometabolic state of 
a patient should always be taken into consideration when 
NT-pro-BNP is assessed as a marker of cardiac function.
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